Using vaccine responses to plumb the immunologic consequences of tumor necrosis factor blockade with etanercept

Journal of Rheumatology

Volumn 31, Issue 7, 2004, Pages 1238-1240

  Scheifele, David W ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CORTICOSTEROID; ETANERCEPT; INFLIXIMAB; METHOTREXATE; PNEUMOCOCCUS VACCINE; POLYSACCHARIDE VACCINE; TUMOR NECROSIS FACTOR;

ANTIBODY PRODUCTION; B LYMPHOCYTE; CANDIDIASIS; CLINICAL TRIAL; COCCIDIOIDOMYCOSIS; EDITORIAL; GRANULOMATOSIS; HISTOPLASMOSIS; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNIZATION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LISTERIOSIS; LOBAR PNEUMONIA; MYCOBACTERIOSIS; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; SEPSIS; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS INFECTION; T LYMPHOCYTE; TUBERCULOSIS;

ANTIRHEUMATIC AGENTS; BIOLOGICAL RESPONSE MODIFIERS; HUMANS; IMMUNITY; IMMUNOGLOBULIN G; PNEUMOCOCCAL VACCINES; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA; VACCINES;

EID: 3042807867     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (11)

1. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha neutralizing agent. N Engl J Med 2001;345:1098-104.
2. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004;38:1261-5.
3. Ritz MA, Jost R. Severe pneumococcal pneumonia following treatment with infliximab for Crohn's disease [letter]. Inflamm Bowel Dis 2001;7:327.
4. Baghai M, Osmon DR, Wolk DM, Wold LE, Haidukewych GJ, Matteson EL. Fatal sepsis in a patient with rheumatoid arthritis treated with etanercept. Mayo Clin Proc 2001;76:653-6.
5. Phillips K, Husni ME, Karlson EW, Coblyn JS. Experience with etanercept in an academic medical center: are infection rates increased? Arthritis Rheum 2002;47:17-21.
6. Moreland LW, Bucy, RP, Weinblatt ME, Mohler KM, Spencer-Green GT, Chatham WW. Immune function in patients with rheumatoid arthritis treated with etanercept. Clin Immunol 2002;103:13-21.
7. Rothe J, Lesslauer W, Lotscher H, et al. Mice lacking the tumor necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature 1993;364:798-802.
8. Pasparakis M, Alexopoulou L, Episkopou V, Kollias G. Immune and inflammatory responses in TNF alpha-deficient mice: a critical requirement for TNF alpha in the formation of primary B cell follicles, follicular dendritic networks and germinal centers, and in the maturation of the humoral immune response. J Exp Med 1996;124:1397-411.
9. Mease PJ, Ritchlin CT, Martin RW, et al. Pneumococcal vaccine responses in psoriatic arthritis patients during treatment with etanercept. J Rheumatol 2004:31:1356-61.
10. Musher DM, Watson DA, Baughn RE. Genetic control of the immunologic response to pneumococcal capsular polysaccharides. Vaccine 2001;19:623-7.
11. Henriques B, Kalin M, Ortqvist A, et al. Molecular epidemiology of Streptococcus pneumoniae causing invasive disease in 5 countries. J Infect Dis 2000;182:833-9.